Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (711-720 of 759) with videos related to

Pageof 76
Sort By:
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Nature Medicine|November 15, 2016
IAP antagonists induce anti-tumor immunity in multiple myelomaMarta Chesi, Noweeda N Mirza, Victoria M Garbitt, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Blood Cancer Journal|March 9, 2019
Natural history of multiple myeloma with de novo del(17p)Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Cancer Cell|August 19, 2007
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myelomaJonathan J Keats, Rafael Fonseca, Marta Chesi, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
Journal of Cardiac Failure|September 2, 2019
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate UtilizationSharmila Dorbala, Yukio Ando, Sabahat Bokhari, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|August 31, 2019
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilizationSharmila Dorbala, Yukio Ando, Sabahat Bokhari, et al.
Pageof 76

Showing results (711-720 of 759) with videos related to

Sort By:
Pageof 76
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Nature Medicine|November 15, 2016
IAP antagonists induce anti-tumor immunity in multiple myelomaMarta Chesi, Noweeda N Mirza, Victoria M Garbitt, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Blood Cancer Journal|March 9, 2019
Natural history of multiple myeloma with de novo del(17p)Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Cancer Cell|August 19, 2007
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myelomaJonathan J Keats, Rafael Fonseca, Marta Chesi, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
Journal of Cardiac Failure|September 2, 2019
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate UtilizationSharmila Dorbala, Yukio Ando, Sabahat Bokhari, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|August 31, 2019
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilizationSharmila Dorbala, Yukio Ando, Sabahat Bokhari, et al.
Pageof 76